GLP-1s aren't increasing penis sizes worldwide
Rosenstock J., Hanefeld M., Gentile S., Aronson R
In that study, the highest dose group reported an average weight loss of 28.7% at 68 weeks
GLP-1s Show Promise, but New Uses Arent Here Yet Editorial Sources and Fact-Checking GLP-1 Agonists
In particular, retatrutide, a triple agonist targeting GLP-1 receptors, GIP, and glucagon receptors, has demonstrated substantial metabolic benefits, raising interest in its potential for treating substance use disorders as well (Jastreboff et al
Description For In Vitro Research Use Only Not for Human or Veterinary Application Specifications: Quantity: 10mg | 20mg | 30mg | 40 mg Form: Lyophilized Powder Intended Use: This compound is intended strictly for in vitro laboratory research by qualified professionals